Recognition of Risk for Clinically Significant Drug Interactions among HIV‐Infected Patients Receiving Antiretroviral Therapy | Zendy

John G. EvansJones | Zendy; Lucy E. Cottle | Zendy; David Back | Zendy; Sara Gibbons | Zendy; Nicholas J. Beeching | Zendy; Peter B. Carey | Zendy; Saye Khoo | Zendy

Open Access

Recognition of Risk for Clinically Significant Drug Interactions among HIV‐Infected Patients Receiving Antiretroviral Therapy

Author(s) -

John G. EvansJones,

Lucy E. Cottle,

David Back,

Sara Gibbons,

Nicholas J. Beeching,

Peter B. Carey,

Saye Khoo

Publication year - 2010

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/652149

Subject(s) - medicine , drug , antiretroviral drug , antiretroviral therapy , sida , drug interaction , human immunodeficiency virus (hiv) , viral disease , viral load , pharmacology , immunology

We assessed the risk of clinically significant drug interactions in patients receiving antiretrovirals, and their recognition by physicians. Clinically significant drug interactions were recorded in 27% of 159 patients, with 15% of interactions potentially lowering antiretroviral concentrations. Risk of clinically significant drug interactions was significantly related to receipt of protease inhibitors. Only 36% of clinically significant drug interactions were correctly identified by physicians.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research